besipirdine

Besipirdine (HP749) is a small molecule dual-acting agent that functions as an alpha-2 adrenergic receptor antagonist and a monoamine reuptake inhibitor, specifically targeting norepinephrine and serotonin transporters. Originally developed by Hoechst-Roussel for the treatment of Alzheimer's disease due to its neuromodulatory effects, it was later licensed and developed by UroGene SA for the treatment of overactive bladder (OAB). In the context of OAB, the drug was intended to improve bladder storage and reduce involuntary contractions by modulating neurotransmission. Despite reaching Phase 2 clinical trials for OAB, including randomized placebo-controlled studies at 20 mg doses, development was discontinued. UroGene was eventually acquired by Pierre Fabre in 2004, and the program did not proceed to further stages.

Other names

besipirdine hydrochloride